- Home
- GOOD vs SION Comparison
GOOD vs SION Comparison
Compare GOOD & SION Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOOD
- SION
- Stock Information
- Founded
- GOOD 2003
- SION 2019
- Country
- GOOD United States
- SION United States
- Employees
- GOOD N/A
- SION N/A
- Industry
- GOOD Real Estate Investment Trusts
- SION
- Sector
- GOOD Real Estate
- SION
- Exchange
- GOOD Nasdaq
- SION NYSE
- Market Cap
- GOOD 670.2M
- SION 564.4M
- IPO Year
- GOOD N/A
- SION 2025
- Fundamental
- Price
- GOOD $14.38
- SION $14.49
- Analyst Decision
- GOOD Hold
- SION Strong Buy
- Analyst Count
- GOOD 1
- SION 1
- Target Price
- GOOD $15.00
- SION $32.00
- AVG Volume (30 Days)
- GOOD 399.0K
- SION 127.9K
- Earning Date
- GOOD 08-05-2025
- SION 05-12-2025
- Dividend Yield
- GOOD 8.35%
- SION N/A
- EPS Growth
- GOOD N/A
- SION N/A
- EPS
- GOOD 0.30
- SION N/A
- Revenue
- GOOD $151,168,000.00
- SION N/A
- Revenue This Year
- GOOD $4.73
- SION N/A
- Revenue Next Year
- GOOD $2.84
- SION N/A
- P/E Ratio
- GOOD $48.74
- SION N/A
- Revenue Growth
- GOOD 3.01
- SION N/A
- 52 Week Low
- GOOD $12.67
- SION $7.26
- 52 Week High
- GOOD $17.88
- SION $25.19
- Technical
- Relative Strength Index (RSI)
- GOOD 49.48
- SION N/A
- Support Level
- GOOD $14.37
- SION N/A
- Resistance Level
- GOOD $14.59
- SION N/A
- Average True Range (ATR)
- GOOD 0.22
- SION 0.00
- MACD
- GOOD -0.01
- SION 0.00
- Stochastic Oscillator
- GOOD 21.69
- SION 0.00
About GOOD Gladstone Commercial Corporation Real Estate Investment Trust
Gladstone Commercial Corp is a real estate investment trust, which engages in investing and owning net leased industrial, commercial, and retail real property and making long-term industrial and commercial mortgage loans. Its portfolio consists of single-tenant commercial, industrial real properties, and medical properties nationwide. Its principal investment objectives are to generate income from rental properties.
About SION SIONNA THERAPEUTICS INC
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.